In the ER-MGSIN, chr4q28 interacted with a wide range of gene sets in the ER+ specific manner, such as target genes of ER, progesterone receptor (PGR), and androgen receptor (AR), response genes of sodium arsenite treatment (a compound that sensitizes ovarian cells to cisplatin36, 37), gene sets characterizing ovarian cancer subtypes, and other cytobands (Supplementary Table S6E), strongly suggesting the involvement of chr4q28 in ER modulation in ovarian cancer. This evidence concerns the gene ESR1 and ovarian carcinoma.